GenSight Biologics

Focus:

Type: Public Corporation
Founded: 2012
HQ: France


Our mission is to turn scientific advances in gene therapy into novel treatments for patients with severe degenerative diseases of the eye and the central nervous system.

Our initial focus is on severe retinal diseases, with the goal of preserving or restoring vision in patients who suffer from sight-threatening ophthalmic diseases. We have been using an integrated development platform based on the combination of a gene therapy-based approach with technologies such as Mitochondrial Target Sequence (MTS) and optogenetics. We are proud of the two promising product candidates that, to date, have advanced to the stage of being tested in clinical trials. And we are investigating others.


Leadership
Bernard Gilly
CEO
Past Roles
Founder (Pixium Vision)


Financial Performance



Funding


Raised Capital
Year
Type
Offered / Sold Amount
Filings
Reported by Press*
Round
2013
41.60M USD
Series A
2015
35.53M USD
Series B
2016
44M USD
Post-IPO Equity
Known Investors
Name
Type
HQ
Other Relevant Investments
Venture Capital
United Kingdom
Investment Bank
United States
Venture Capital
Switzerland
Venture Capital
United Kingdom
Asset Management
United States
Venture Capital
United Kingdom
Corporate Venture
Switzerland
Hedge Fund
United States
Hedge Fund
Israel
Venture Capital
United States
*More data available at: [CB Insights] [CrunchBase] [PitchBook]

Related
News